Mario Botta

1.5k total citations
56 papers, 1.1k citations indexed

About

Mario Botta is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Mario Botta has authored 56 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 8 papers in Surgery and 7 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Mario Botta's work include Occupational and environmental lung diseases (22 papers), Pleural and Pulmonary Diseases (10 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (4 papers). Mario Botta is often cited by papers focused on Occupational and environmental lung diseases (22 papers), Pleural and Pulmonary Diseases (10 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (4 papers). Mario Botta collaborates with scholars based in Italy, United States and Malaysia. Mario Botta's co-authors include Corrado Magnani, Benedetto Terracini, C Ivaldi, B. Castagneto, Arianna Mancini, A Andrion, Silvia Zai, Manlio Mencoboni, E. Piccolini and P G Betta and has published in prestigious journals such as Journal of Clinical Oncology, Medicine & Science in Sports & Exercise and British Journal of Cancer.

In The Last Decade

Mario Botta

53 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mario Botta Italy 18 593 144 126 116 114 56 1.1k
Claire H. Pernar United States 13 407 0.7× 234 1.6× 40 0.3× 125 1.1× 48 0.4× 24 994
Nobuaki Shigematsu Japan 16 660 1.1× 57 0.4× 66 0.5× 35 0.3× 116 1.0× 64 1.3k
Gavino Faa Italy 18 245 0.4× 66 0.5× 172 1.4× 25 0.2× 37 0.3× 64 884
Mitsuyoshi Utsugi Japan 22 379 0.6× 239 1.7× 28 0.2× 69 0.6× 60 0.5× 53 1.3k
Jesper Kers Netherlands 21 270 0.5× 155 1.1× 120 1.0× 162 1.4× 14 0.1× 78 1.5k
Ronald G. Vincent United States 15 495 0.8× 340 2.4× 51 0.4× 24 0.2× 50 0.4× 27 1.1k
Patrizia Viola United Kingdom 14 674 1.1× 452 3.1× 193 1.5× 19 0.2× 58 0.5× 41 1.5k
Avneesh Gupta United States 17 227 0.4× 89 0.6× 170 1.3× 47 0.4× 20 0.2× 68 1.1k
Mihnea Zdrenghea Romania 17 129 0.2× 129 0.9× 28 0.2× 61 0.5× 29 0.3× 116 1.2k
Ken Y. Yoneda United States 21 646 1.1× 271 1.9× 61 0.5× 45 0.4× 30 0.3× 63 1.6k

Countries citing papers authored by Mario Botta

Since Specialization
Citations

This map shows the geographic impact of Mario Botta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mario Botta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mario Botta more than expected).

Fields of papers citing papers by Mario Botta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mario Botta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mario Botta. The network helps show where Mario Botta may publish in the future.

Co-authorship network of co-authors of Mario Botta

This figure shows the co-authorship network connecting the top 25 collaborators of Mario Botta. A scholar is included among the top collaborators of Mario Botta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mario Botta. Mario Botta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Botta, Mario, et al.. (2015). Feasibility of bendamustine in elderly patients with b-cell non hodgkin lymphomas. Annals of Oncology. 26. vi150–vi150.
3.
Ceresoli, Giovanni Luca, Federica Grosso, Paolo Andrea Zucali, et al.. (2014). Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey. British Journal of Cancer. 111(2). 220–226. 29 indexed citations
4.
Ceresoli, Giovanni Luca, Paolo Andrea Zucali, Manlio Mencoboni, et al.. (2013). Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. British Journal of Cancer. 109(3). 552–558. 68 indexed citations
5.
Altomare, Emanuela, et al.. (2012). Increased frequency of circulating invariant natural killer T cells in malignant pleural mesothelioma patients. Cancer Biology & Therapy. 13(9). 702–711. 4 indexed citations
6.
Fantuzzi, E., Basilio Morelli, G. Gualdrini, et al.. (2011). ENEA extremity dosemeter based on LiF(Mg,Cu,P) to evaluate Hp(3, ). Radiation Protection Dosimetry. 144(1-4). 187–191. 6 indexed citations
7.
Giaccone, Giorgio, Michela Morbin, Fabio Moda, et al.. (2010). Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features. Acta Neuropathologica. 120(6). 803–812. 58 indexed citations
8.
Trincheri, Nicol Francesca, et al.. (2010). Aurora B kinase and malignant mesothelioma.. Journal of Clinical Oncology. 28(15_suppl). e21021–e21021. 2 indexed citations
9.
Betti, Marta, Monica Neri, Daniela Ferrante, et al.. (2008). Pooled analysis of NAT2 genotypes as risk factors for asbestos-related malignant mesothelioma. International Journal of Hygiene and Environmental Health. 212(3). 322–329. 11 indexed citations
10.
Castagneto, B., Mario Botta, Enrico Aitini, et al.. (2007). Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Annals of Oncology. 19(2). 370–373. 102 indexed citations
11.
Castagneto, B., et al.. (2005). Cisplatin and Gemcitabine in Malignant Pleural Mesothelioma: A Phase II Study. American Journal of Clinical Oncology. 28(3). 223–226. 44 indexed citations
12.
13.
Manetti, Fabrizio, Federico Corelli, Giovannella Strappaghetti, & Mario Botta. (2002). Arylpiperazines with Affinity Toward a1-Adrenergic Receptors. Current Medicinal Chemistry. 9(13). 1303–1321. 20 indexed citations
14.
Castagneto, B., Silvia Zai, Luciano Mutti, et al.. (2001). Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion. Lung Cancer. 31(2-3). 303–310. 67 indexed citations
15.
Alabiso, Oscar, Maurizio Grosso, Isabella Chiappino, et al.. (2000). Intra-Arterial Continuous Infusion for Treatment of Pancreatic and Biliary Tract Cancer: A Dose-Escalation Study of Fluorouracil Combined with Gemcitabine. International Journal of Gastrointestinal Cancer. 27(3). 225–234. 11 indexed citations
16.
Botta, Mario, et al.. (1997). Ethik des bauens = The ethics of building.
17.
Zerilli, Andrea, Mario Botta, & Bruno Apolloni. (1997). Improving magnetotelluric data degraded by correlated noise with robust regression analysis and recurrent neural networks. 124. 366–369. 4 indexed citations
18.
Botta, Mario, et al.. (1995). Il Museo di arte moderna e contemporanea di Trento e Rovereto. 1 indexed citations
19.
Brambillasca, Claudio, Mario Botta, Massimo Lemma, et al.. (1995). Improvement of Cardiac Function by Allopurinol in Patients Undergoing Cardiac Surgery. Journal of Cardiovascular Pharmacology. 25(1). 119–125. 68 indexed citations
20.
Lemma, Massimo, Paolo Vanelli, Luigi Beretta, et al.. (1992). Cardiac Surgery in HIV-positive Intravenous Drug Addicts: Influence of Cardiopulmonary Bypass on the Progression to AIDS. The Thoracic and Cardiovascular Surgeon. 40(5). 279–282. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Claire H. Pernar Breakdown of academic impact, for papers by Nobuaki Shigematsu Breakdown of academic impact, for papers by Gavino Faa Breakdown of academic impact, for papers by Mitsuyoshi Utsugi Breakdown of academic impact, for papers by Jesper Kers Breakdown of academic impact, for papers by Ronald G. Vincent Breakdown of academic impact, for papers by Patrizia Viola Breakdown of academic impact, for papers by Avneesh Gupta Breakdown of academic impact, for papers by Mihnea Zdrenghea Breakdown of academic impact, for papers by Ken Y. Yoneda
Rankless by CCL
2026